

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/588,379	
			Filing Date	August 2, 2006	
			First Named Inventor	Tomas J. EKSTRÖM	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	4	Attorney Docket Number	5156-0103PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-5,939,455	08-17-1999	REPHAEL		
AB*	US-5,605,930	02-25-1997	SAMID		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	WO-03/017763	03-06-2003			
BB	WO-03/084611	10-16-2003			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP §61.04. \* Excerpt: Office that issued the document, by the two-letter code (WIPO Standard ST 3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
CA	ASKLUND THOMAS ET AL:	"Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene." EXPERIMENTAL CELL RESEARCH, vol. 284, no. 2, 1 April 2003 (2003-04-01), pages 185-195, XP002377912 ISSN: 0014-4827 page 191-194, paragraph entitled "Discussion"; figure 6.		
CB	ALMQVIST P M ET AL:	"DIFFERENTIATION OF HUMAN PRIMARY GLIOBLASTOMA CELLS BY A PHENYL BUTYRATE." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, pages Abstract No. 802.8; URL: <a href="http://sf.XP009065441">http://sf.XP009065441</a> & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002. Abstract.		
CC	ALTENBURG B C ET AL:	"MODIFICATION OF THE PHENOTYPE OF MURINE SARCOMA VIRUS TRANSFORMED CELLS BY SODIUM BUTYRATE EFFECTS OF MORPHOLOGY AND CYTOSKELETAL ELEMENTS" EXPERIMENTAL CELL RESEARCH, vol. 102, no. 2, 1976, pages 223-231, XP009065490 ISSN: 0014-4827, page 228-231, paragraph entitled "Discussion".		
CD	JIAN WEIGUO ET AL:	"Combination of adenovirus mediated suicide gene therapy with the histone deacetylase inhibitors butyrate, phenylbutyrate and electroporation in bladder cancer in vitro and in vivo." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07), pages 1300-1301, XP001247005 & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003 ISSN: 0197-016X. Abstract.		

Examiner Signature	/Janet Epps Smith/	Date Considered	11/05/2009
--------------------	--------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/588,379
Filing Date	August 2, 2006
First Named Inventor	Tomas J. EKSTRÖM
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	5156-0103PUS1

Sheet 2 of 4

CE	CHUNG Y L ET AL: "A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: Implications for radiosensitization and EBV-targeted therapy." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, APR. 2000, vol. 6, no. 4, April 2000 (2000-04), pages 1452-1458, XP002377913 ISSN: 1078-0432 page 1456-1457, paragraph entitled "Discussion".	
CF	KWON H ET AL: "HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE THERAPY DELIVERED BY RETROVIRAL OR ADENOVIRAL VECTOR IN MOUSE MODEL OF LEWIS LUNG CARCINOMA" TUBERCULOSIS AND RESPIRATORY DISEASES, SN, KR. vol. 49, no. 3, September 2000 (2000-09), pages 298-309, XP001208119 ISSN: 0378-0086, abstract on pages 298-299.	
CG	CAMACHO L H ET AL: "Transcription modulation. A pilot study of sodium phenylbutyrate plus 5-azacytidine," BLOOD, vol. 98, no. 11, Part 1, 18 November 2001 (2001-11-18), page 480A, XP009065447 & 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1, ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, ISSN: 0006-4971, Abstract.	
CH	HUANG Y ET AL: "Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, OCT. 1998, vol. 4, no. 10, October 1998 (1998-10), pages 2503-2509, XP002377914, ISSN: 1078-0432, page 2508, paragraph entitled "Discussion."	
CI	AMMERPOHL O ET AL: "HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 324, no. 1, 5 November 2004 (2004-11-05), pages 8-14, XP004605891, ISSN: 0006-291X, page 12-13, paragraph entitled "Discussion."	
CJ	ROBE PIERRE A ET AL: "Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: Correlation with gap-junction intercellular communication", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 25, no. 1, July 2004 (2004-07), pages 187-192, XP009065479, ISSN: 1019-6439, 189-191, paragraph entitled "Discussion."	
CK	ASKLUND T ET AL: "Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells," EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 40, no. 7, May 2004 (2004-05), pages 1073-1081, XP004502880, ISSN: 0959-8049, page 1077-1080, paragraph entitled "Discussion."	
CL	MARKS ET AL: "Histone deacetylases and cancer: causes and therapies," Nature Reviews, vol. 1, pp. 194-202.	
CM	JOHNSTONE: "Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer," Nature Reviews, vol. 1, pp. 287-299.	
CN	BEDALOV ET AL: "Identification of a small molecule inhibitor of Sir2p," PNAS, vol. 98, no. 26, pp. 15113-15118.	
CO	SANDA ET AL: "Bystander effects of nucleoside analogs phosphorylated in the cytosol or mitochondria," Biochemical and Biophysical Research Communications, 287, pp. 1163-1166.	
CP	YOSHIDA ET AL: "Clinical gene therapy for brain tumors, Liposomal delivery of anticancer molecule to glioma," Jour Neuro-Oncology, 65, pp. 261-267.	

Examiner Signature	/Janet Epps Smith/	Date Considered	11/05/2009
--------------------	--------------------	-----------------	------------

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 4

## **Complete if Known**

Application Number	10/588,379
Filing Date	August 2, 2006
First Named Inventor	Tomas J. EKSTRÖM
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	5156-0103PUS1

CQ	BERG ET AL: "Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate," Cancer, Chemotherapy and Pharmacology, pp. 1-11.
CR	CARDUCCI ET AL: "A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule," Clinical Cancer Research, vol. 7, pp. 3047-3055.
CS	MCILICHAIR ET AL: "Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines," Clinical Cancer Research, vol. 4, pp. 3069-3076.
CT	NEWMARK ET AL: "Butyrate and phenylacetate as differentiation agents: Practical problems and opportunities," Journal of Cellular Biochemistry, supplement 22, pp. 247-253.
CU	KITAZONO ET AL: " Adenovirus HSV-TK construct with thyroid-specific promoter: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway," Int. J. Cancer, 99, pp. 453-459.
CV	KITIZONO ET AL: "Construction of gene therapy vectors targeting thyroid cells: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells," The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 2, pp. 834-840.
CW	KITAZONO ET AL: "Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na+/I symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells," The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 7, pp. 3430-3435.
CX	BARTOLI ET AL: "Effect of trichostatin a and 5'-azacytidine on transgene reactivation in U937 transduced cells," Pharmacol Res., 48(1):111-8.
CY	ABOODY ET AL: "Neural stem cells display extensive tropism for pathology in adult brain: Evidence from Intracranial gliomas," PNAS, vol. 97, no. 23, pp. 12848-12851.
CZ	DUNN ET AL: "The neurosurgeon as local oncologist: Cellular and molecular neurosurgery in malignant glioma therapy," Neurosurgery, vol. 52, no. 6, pp. 1411-1424.
CA1	YAMAMOTO ET AL: "A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma," Cancer Gene Therapy, 10, pp. 179-186.
CB1	SUTTON ET AL: "Adenovirus-mediated suicide gene therapy for experimental bladder cancer," Urology 49 (2), pp. 173-180.
CC1	BI ET AL: "Experimental study of thymidine kinase gene therapy of neuroblastoma in vitro and in vivo," Pediatr Surg Int, 19, pp. 400-405.
CD1	GERMANO ET AL: "Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas," Journal of Neuro-Oncology, 65, pp. 279-289.
CE1	GEROLAMI ET AL: "Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors," Journal of Hepatology, 40, pp. 291-297.
CF1	BARNES ET AL: "Current strategies in gene therapy for ovarian cancer," Current Opinion in Obstetrics and Gynecology, pp. 47-51.
CG1	KUBO ET AL: "Phase 1 dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer," Human Gene Therapy, 14, pp. 227-241.

Examiner Signature	/Janet Epps Smith/	Date Considered	11/05/2009
--------------------	--------------------	-----------------	------------

Birch, Stewart, Kolasch & Birch, LLP

GMM/JMK/sh

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/588,379
				Filing Date	August 2, 2006
				First Named Inventor	Tomas J. EKSTRÖM
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	5156-0103PUS1

CH1	PULKKANEN ET AL: "The combination of HSV-1k and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice." Cancer Gene Therapy, 9, pp. 908-916.
-----	---

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Janet Epps Smith/	Date Considered	11/05/2009
-----------------------	--------------------	--------------------	------------

Birch, Stewart, Kellogg &amp; Birch, LLP

GMM/JMK/eh

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.E./